Trends in Enzyme Inhibition and Activation in Drug Design – Part-I

Author(s): Athina Geronikaki.

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 4 , 2019

Become EABM
Become Reviewer

[1]
Eleftheriou, P.; Geronikaki, A.; Petrou, A. PTP1B inhibition, A promising approach for the treatment of diabetes type II. Curr. Topics. Med. Chem., 2019, 19(4), 246-263. [PMID: 30714526].
[2]
Saxena, M.; Dubey, R. Target enzyme in Alzheimer’s disease: Acetylcholinesterase inhibitors. Curr. Topics. Med. Chem., 2019, 19(4), 264-275. [PMID: 30706815].
[3]
Rekka, E.A.; Kourounakis, P.N.; Pantelidou, M. Xenobiotic metabolising enzymes: Impact on pathologic conditions, drug interactions and drug design. Curr. Topics. Med. Chem., 2019, 19(4), 276-291. [PMID: 30706817].
[4]
Merlani, M.; Barbakadze, V.; Amiranashvili, L.; Gogilashvili, L.; Poroikov, V.; Petrou, A.; Geronikaki, A.; Ciric, A.; Glamoclija, J.; Sokovic, M. New caffeic acid derivatives as antimicrobial agents: Design, synthesis, evaluation and docking. Curr. Topics. Med. Chem., 2019, 19(4), 292-304. [PMID: 30674263].
[5]
Shaik, A.; Agarwal, H.K.; Bhakuni, R.; Kirubakaran, S. Novel pyrazolo[4, 3-c]quinolin-3-one derivatives as PDE5A inhibitors. Curr. Topics. Med. Chem., 2019, 19(4), 305-315. [PMID: 30747070].


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 4
Year: 2019
Page: [244 - 245]
Pages: 2
DOI: 10.2174/156802661904190411090238

Article Metrics

PDF: 18
HTML: 1